PsART-ID inception cohort: clinical characteristics, treatment choices and outcomes of patients with psoriatic arthritis.
Adult
Antirheumatic Agents
/ therapeutic use
Arthritis, Psoriatic
/ drug therapy
Cohort Studies
Drug Prescriptions
/ statistics & numerical data
Female
Finger Joint
/ physiopathology
Glucocorticoids
/ therapeutic use
Humans
Joint Deformities, Acquired
/ physiopathology
Male
Methotrexate
/ therapeutic use
Middle Aged
Nail Diseases
/ drug therapy
Patient Reported Outcome Measures
Registries
Sulfasalazine
/ therapeutic use
Tumor Necrosis Factor Inhibitors
/ therapeutic use
early disease
inception cohort
psoriatic arthritis
Journal
Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501
Informations de publication
Date de publication:
06 04 2021
06 04 2021
Historique:
received:
01
07
2020
revised:
04
09
2020
pubmed:
25
10
2020
medline:
29
6
2021
entrez:
24
10
2020
Statut:
ppublish
Résumé
Our aim is to understand clinical characteristics, real-life treatment strategies, outcomes of early PsA patients and determine the differences between the inception and established PsA cohorts. PsArt-ID (Psoriatic Arthritis- International Database) is a multicentre registry. From that registry, patients with a diagnosis of PsA up to 6 months were classified as the inception cohort (n==388). Two periods were identified for the established cohort: Patients with PsA diagnosis within 5-10 years (n = 328), ≥10 years (n = 326). Demographic, clinical characteristics, treatment strategies, outcomes were determined for the inception cohort and compared with the established cohorts. The mean (s.d.) age of the inception cohort was 44.7 (13.3) and 167/388 (43.0%) of the patients were male. Polyarticular and mono-oligoarticular presentations were comparable in the inception and established cohorts. Axial involvement rate was higher in the cohort of patients with PsA ≥10 years compared with the inception cohort (34.8% vs 27.7%). As well as dactylitis and nail involvement (P = 0.004, P = 0.001 respectively). Both enthesitis, deformity rates were lower in the inception cohort. Overall, 13% of patients in the inception group had a deformity. MTX was the most commonly prescribed treatment for all cohorts with 10.7% of the early PsA patients were given anti-TNF agents after 16 months. The real-life experience in PsA patients showed no significant differences in the disease pattern rates except for the axial involvement. The dactylitis, nail involvement rates had increased significantly after 10 years from the diagnosis and the enthesitis, deformity had an increasing trend over time.
Identifiants
pubmed: 33097960
pii: 5937239
doi: 10.1093/rheumatology/keaa663
doi:
Substances chimiques
Antirheumatic Agents
0
Glucocorticoids
0
Tumor Necrosis Factor Inhibitors
0
Sulfasalazine
3XC8GUZ6CB
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1755-1762Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.